France Artificial Intelligence in Life Sciences Market Insight
Published: 05 June 2026 | Report Format: Electronic (PDF)
France Artificial Heart Market is expected to experience an increase at a rate of 10.55% owing to high severe shortage of donor hearts rising incidence of cardiovascular disease, technological miniaturization & biomaterials, favorable regulatory & innovation ecosystem.
France Artificial Heart Market Insights Forecasts to 2035
- The France Artificial Heart Market Size Was Estimated USD 66.2 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 10.55% from 2025 to 2035
- The France Artificial Heart Market Size is Expected to rise around USD 180.42 Million by 2035
Notable Insights for the France Artificial Heart Market
- The type-based segmentation indicates that Due to improved survival outcomes, patient mobility, transplant bridging, and long-term heart failure management, the Ventricular Assist Devices (VADs) category is expected to have a 77% market share in 2025.
- The application-based segmentation shows that the destination therapy (DT) segment would account for around 35.4% of the market due to an increase in patients of severe heart failure that need ongoing mechanical circulatory support.
- France's artificial heart sector benefits from public-private ventures like CorNovum, backed 50-50 by Bpifrance and the French State, contributing €17 million toward commercialization and innovation acceleration.
- European Union support strengthened France’s artificial heart innovation ecosystem, with CARMAT securing a €30 million European Investment Bank loan to advance clinical trials, commercialization, and manufacturing expansion.
Download the eBook (ToC)
Research Methodologies Used to Analyze the France Artificial Heart Market The France Artificial Heart Market is analyzed through a combination of primary and secondary research methodologies to ensure accurate assessment of market dynamics and future growth prospects. Primary research includes interviews and discussions with artificial heart manufacturers, medical device companies, cardiac surgeons, hospitals, research institutes, healthcare providers, regulatory authorities, and industry experts to evaluate demand patterns, technological advancements, clinical adoption trends, and competitive developments. Secondary research involves the examination of company annual reports, government healthcare publications, industry journals, scientific literature, clinical trial databases, regulatory filings, and reports from healthcare and medical device associations related to cardiovascular technologies and artificial organs. Market sizing, forecasting models, trend analysis, and investment assessment techniques are utilized to estimate market value, growth potential, emerging opportunities, pricing trends, and technological developments across the France Artificial Heart Market.
Decisions Advisors Research Methodology: Trusted Insights for Strategic Decision-Making
What is Decisions Advisors Research?
Decisions Advisors research delivers comprehensive market intelligence through detailed industry analysis, competitive benchmarking, trend forecasting, and data-driven business insights. Our research methodology combines advanced analytical frameworks with extensive primary and secondary research to help organizations make informed and strategic business decisions.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the France Artificial Heart Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in France Artificial Heart Market
- Abbott Laboratories
- Medtronic
- Boston Scientific Corporation
- Getinge AB
- Edwards Lifesciences Corporation
- SynCardia Systems, LLC
- Carmat SA
- CorWave SA
- FineHeart SA
- Abbott France SAS
Recent Developments:
- In June 2025, CARMAT achieved the first 2 commercial Aeson artificial heart implants in Israel, marking its first commercialization outside the EU and expanding international adoption.
- In May 2025, CARMAT completed enrollment of 52 patients in the EFICAS clinical study and secured French regulatory approval for 21 additional Aeson implants, strengthening reimbursement prospects.
Market Segmentation:
France Artificial Heart Market, By Type
- Heart-Lung Machine
- Mechanical Heart
- Total Artificial Hearts
- Ventricular Assist Devices (VADs)
France Artificial Heart Market, By End User
- Hospitals
- ASCs
- Specialty Clinics
- Others
France Artificial Heart Market, By Application
- Bridge to Transplant (BTT)
- Bridge to Candidacy (BTC)
- Destination Therapy (DT)
- Bridge to Recovery (BTR))
Expert Views:
The France Artificial Heart Market is expected to exhibit strong long-term growth prospects due to a rising incidence of end-stage heart failure, limited donor heart availability and increasing innovation in theartificial heartsystems technology. Backing from public-private ventures, encouraging regulatory policies, and huge investment in the clinical development are the leading factors fueling the growth of the market. Among the various types of artificial hearts in demand. Ventricular Assist Devices and Destination Therapy held significant market share. France is likely to continue to be a primary European market center for artificial heart innovation, commercialization and the most sophisticated cardiovascular care up to 2035.
Author: Komal and Radhika By Spherical Insights and Consulting